| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $86.0M | — | +108.4% |
| SG&A Expense | $39.1M | — | +145.8% |
| Operating Income | -$125.1M | — | -118.8% |
| Net Income | -$121.0M | — | -134.1% |
| EPS (Basic) | -$1.69 | — | -108.6% |
| EPS (Diluted) | -$1.69 | — | -108.6% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $114.4M | -67.8% | +107.6% |
| Short-term Investments | $482.4M | +34.1% | -9.8% |
| Current Assets | $615.8M | -15.5% | +1.6% |
| Total Assets | $621.7M | -15.4% | +1.9% |
| Current Liabilities | $45.1M | -15.5% | +106.2% |
| Long-term Debt | $75.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$106.5M | — | -95.8% |
| Capital Expenditures | $23K | — | -87.7% |
| Investing Cash Flow | -$137.8M | — | -999.8% |
| Financing Cash Flow | $3.9M | — | +157.1% |
| Free Cash Flow | -$106.5M | — | -95.1% |
| +47.4% |
| Total Liabilities | $122.0M | -6.3% | +62.4% |
| Stockholders' Equity | $499.7M | -17.3% | -6.6% |